Skip to content

Earnings yield at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
3.1%+2.7pp
Viatris logo
ViatrisVTRS
-1.9%-0.9pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-9.9%-2.8pp
ALN
Alnylam PharmaceuticalsALNY
1.1%+0.8pp
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
15.1%+11.5pp
Amgen logo
AmgenAMGN
4.1%+0.6pp

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Calculated from ANI Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's earnings yield?
ANI Pharmaceuticals (ANIP) reported earnings yield of 5.3% in Q1 2026.
How has ANI Pharmaceuticals's earnings yield changed year-over-year?
ANI Pharmaceuticals's earnings yield increased by 470.1% year-over-year, from -1.4% to 5.3%.
What is the long-term trend for ANI Pharmaceuticals's earnings yield?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's earnings yield has grown at a -1.0% compound annual growth rate (CAGR), from -4.7% to 4.4%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.